Towards Healthcare
Nucleic Acid Drugs Market to Rise at 19.84% CAGR till 2034

Nucleic Acid Drugs Market Growth Fueled by AI Trends

According to market projections, the nucleic acid drugs sector is expected to grow from USD 47.59 million in 2024 to USD 286.13 million by 2034, reflecting a CAGR of 19.84%. The nucleic acid drugs market is expanding due to advances in delivery technologies (lipid nanoparticles, viral vectors) and increasing approvals. North America led the market due to the presence of robust industries.

  • Last Updated: 29 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The nucleic acid drugs market stands at USD 57.03 million in 2025 and is expected to reach USD 286.13 million by 2034, growing at a CAGR of 19.84% from 2024 to 2034.

North America is currently leading the nucleic acid drugs market share by 45% due to the presence of robust industries.

The nucleic acid drugs market includes 6 segments such as by drug type, by therapeutic area, by delivery technology, by end user, by route of administration, and by region. 

Some key players include Arrowhead Pharmaceuticals, Silence Therapeutics, Wave Life Sciences, and Arcturus Therapeutics. 

The growing investment in genetic and rare disease therapies is the factor that drives the market.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.